Amanta Healthcare Ltd (AMANTA) Q2FY27 Concall Summary - Sep-2026 Qtr
Key Takeaways
- The new SteriPort Line 3 is operational and will add approximately INR 60 crore in revenue for FY27, with full utilization expected from November 2026.
- The next growth driver, a Small Volume Parenteral line, is delayed to Q1 FY28 and is projected to add a conservative INR 16 crore in FY28 revenue.
- Management reaffirmed its two-year target of 20%+ revenue CAGR and 25%+ EBITDA margin, signaling confidence despite raw material price pressures and capex delays.
Performance Overview
- Delivered strong performance with a 17% year-on-year growth in top-line, and even faster profit growth.
- Successfully commissioned and operationalized SteriPort Line 3, increasing the company's SteriPort capacity by approximately 75%.
- A 10.8 megawatt captive solar plant became operational, expected to provide structural cost advantages and strengthen the company's ESG profile.
- Significantly strengthened the balance sheet, reducing the debt-to-equity ratio from 3.5 times in FY23 to about 1.1 in FY26.
- Growth is being driven by three pillars: expanding market depth in advanced markets, increasing manufacturing scale, and enhancing operational efficiency.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.
Tone & Disclosure
Log in to Stocksigma to read the Tone & Disclosure section of this summary.